Targeting epiregulin in treatment-damaged tumor microenvironment restrains therapeutic resistance
What makes a great footpath? The answer is key to our happiness and well-being as we age
25 October 2022How evolutionary developmental psychology can explain mental disorders
25 October 2022Targeting epiregulin in treatment-damaged tumor microenvironment restrains therapeutic resistance
A recent study published in Oncogene and led by Dr. Sun Yu’s group at Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences revealed the roles and functional mechanisms of senescence-associated secretory factor epiregulin (EREG) in treatment-damaged tumor microenvironments, providing a new therapeutic target and noninvasive biomarker for treatment of human malignancies including prostate cancer.
